OVERVIEW
Carotid artery angioplasty with stenting (CAS) is a treatment for carotid stenosis that is intended to prevent future stroke. It is an alternative to medical therapy and a less-invasive alternative to carotid endarterectomy (CEA).

PRIOR AUTHORIZATION
Not Applicable

POLICY STATEMENT
BlueCHiP for Medicare and Commercial

Carotid angioplasty without embolic protection is considered not medically necessary as there is insufficient peer-reviewed scientific literature that demonstrates that the procedure is effective.

MEDICAL CRITERIA
None

BACKGROUND
Carotid artery angioplasty with stenting (CAS) is a treatment for carotid stenosis that is intended to prevent future stroke. It is an alternative to medical therapy and a less-invasive alternative to carotid endarterectomy (CEA).

Combined with optimal medical management, carotid angioplasty with or without stenting has been evaluated as an alternative to carotid endarterectomy (CEA). Carotid angioplasty and stenting (CAS) involves the introduction of coaxial systems of catheters, microcatheters, balloons, and other devices. The procedure is most often performed through the femoral artery, but a transcervical approach can also be used to avoid traversing the aortic arch. The procedure typically takes 20–40 minutes. Interventionalists almost uniformly use an embolic protection device (EPD) designed to reduce the risk of stroke caused by thromboembolic material dislodged during CAS. Embolic protection devices can be deployed proximally (with flow reversal) or distally (using a filter). Carotid angioplasty rarely is performed without stent placement.

Proposed advantages of CAS over CEA include:

- General anesthesia is not used (although CEA can be performed under local/regional anesthesia)
- Cranial nerve palsies are infrequent sequelae (although almost all following CEA resolve over time)
- Simultaneous procedures may be performed on the coronary and carotid arteries

The U.S. Food and Drug Administration (FDA) has approved carotid artery stents and EPDs from various manufacturers. Each FDA-approved carotid stent is indicated for combined use with an EPD to reduce risk of stroke in patients considered to be at increased risk for periprocedural complications from CEA who are symptomatic with greater than 50% stenosis, or asymptomatic with greater than 80% stenosis—degree of
stenosis being assessed by ultrasound or angiogram with computed tomography (CT) angiography also
sometimes used. Patients are considered at increased risk for complications during CEA if affected by any
item from a list of anatomic features and comorbid conditions included in each stent system’s Information
for Prescribers.

**COVERAGE**

Benefits may vary between groups/contracts. Please refer to the appropriate Evidence of Coverage,
Subscriber Agreement for applicable Services Not Medically Necessary coverage/benefits.

**CODING**

BlueCHiP for Medicare and Commercial

The following code is not medically necessary:

37216

**RELATED POLICIES**

Preauthorization via Web-Based tool for Procedures

**PUBLISHED**

- **Provider Update** Jan 2015
- **Provider Update** Sep 2013
- **Provider Update** Dec 2012
- **Provider Update** May 2011
- **Provider Update** Jun 2010
- **Provider Update** Jun 2009
- **Provider Update** Sep 2008
- **Provider Update** Oct 2007

**REFERENCES**


2. CMS. Intracranial Percutaneous Transluminal Angioplasty (PTA) with Stenting. January 5, 2007; Transmittal 64: Change Request 5432.


This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member’s subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.